Pharma & Biotech Global Week in Review 19 Aug 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Nexavar (Sorafenib) – India: Patent linkage killed by Delhi High Court and Bayer fined (Spicy IP)

US: Jim Greenwood on data exclusivity and healthcare innovation (BiotechBlog) (IP Watchdog) (Patent Docs)

 
General

SPCs: good for Europe, bad for India? (The SPC Blog)

Strategically challenging transit drug seizures at the WTO: EC vs Netherlands? (Spicy IP)

Pharma patents and article 31bis: where are we now? (IPKat)

Whose right? HIV activists call for people’s property rights (Afro-IP)

Innovation, IP and medical services (IP finance)

Investors saw biotech rebound coming (Patent Docs)

Seeded players – Corporate control in agricultural research (Patenting Lives)

EU: Intellectual Property Institute initiative on paediatric inconsistencies links patent offices (The SPC Blog)

EU: Questions about the codified Regulation No 469/2009 (The SPC Blog)

India: Government of India accepts conclusions of Mashelkar Committee Report (Spicy IP) (Spicy IP)

US: Is biotech/pharma beginning to bounce back? (Patent Docs)

US: BIO files amicus brief in Bilski (Patent Docs)

US: Jim Greenwood on data exclusivity and healthcare innovation (BiotechBlog) (IP Watchdog) (Patent Docs)

US: European biosimilars market may hint at limited US threat (GenericsWeb)

US: Chris Hansen on the Myriad lawsuit (Patents4Life)

 
Products

Effexor (Venlafaxine) – US: Wyeth files suit alleging Alphapharm’s Enlafax infringes its Venlafaxine patent; Generic Health, which recently registered eight Venlafaxine products, not named in the suit (GenericsWeb)

Eloxatin (Oxaliplatin) – US: Hospira stops selling generic Oxaliplatin following Sanofi-Aventis commencing court proceedings to block shipments (GenericsWeb)

Gemzar (Gemcitabine) – US: District Court E D Michigan grants partial summary judgment invalidating Lilly’s method-of-use patent for Gemzar (GenericsWeb)

Nexavar (Sorafenib) – India: Patent linkage killed by Delhi High Court and Bayer fined (Spicy IP)

Pulmicort (Budesonide) – US: AstraZeneca files patent infringement suit against Breath over ANDA to manufacture generic Pulmicort (Patent Docs)

Stelara (Ustekinumab) – US: Abbott files patent infringement suit against Centocor Ortho Biotech over its Stelara product (Patent Docs)

Tamiflu (Oseltamivir) – India: In favour of allowing retail sales of Tamiflu (Spicy IP)

Ultram (Tramadol) – US: Par Pharmaceutical wins on invalidity in Ultram litigation against Purdue, Ortho-McNeils (SmartBrief) (GenericsWeb)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: